Darolutamide significantly improved median metastasis-free survival (MFS) by 22 months (40.4 months with darolutamide plus androgen deprivation therapy (ADT) versus 18.4 months for placebo plus ADT / Positive trend in overall survival with a 29% reduction in risk of death at interim analysis (P=0.045) / Incidence of treatment-emergent adverse events was similar between darolutamide plus ADT and placebo plus ADT/ Health-related quality of life was maintained/ First results from the Phase III ARAMIS trial with the androgen receptor antagonist darolutamide were presented in an oral presentation at American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) 2019 and simultaneously published in The New England Journal of Medicine
Read more

January 16, 2019

Does your community charity need some TLC?

$165,000 in community grants available to charities & not-for-profits across Canada through the 2019 Canada’s Farmers Grow Communities Program
Read more